Podcasts about disease burden

Last Chance: Multiple Myeloma Task Force Podcast Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025. Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma. Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

In this episode of Stanford Legal, host Professor Pamela Karlan interviews her Stanford Law School colleague Professor Lisa Larrimore Ouellette about actions by the Trump administration that Ouellette says are undermining scientific research and jeopardizing America's longstanding global leadership in medicine and innovation. Drawing on an essay she penned for Just Security, Ouellette explains how decades of bipartisan support for federally funded science—an engine of American innovation since World War II—is now at risk. From canceling grants already approved through peer review, to capping essential “indirect cost” reimbursements, she details how these moves threaten not just labs and universities but also patients, whose clinical trials are being abruptly halted.  Ouellette also highlights a second front in her current scholarship: how drug development policy can be better aligned with public health needs. As a member of a National Academies committee, she recently co-authored a report showing that both private investment and federal funding often fail to prioritize diseases causing the greatest suffering. Links:Lisa Larrimore Ouellette >>> Stanford Law pageThe Trump Administration's Multi-Front Assault on Federal Research Funding  >>> Just Security pageStanford Law's Lisa Ouellette Helps Shape New Report on Drug Development Reform  >>> Stanford Lawyer online featureConnect:Episode Transcripts >>> Stanford Legal Podcast WebsiteStanford Legal Podcast >>> LinkedIn PageRich Ford >>>  Twitter/XPam Karlan >>> Stanford Law School PageStanford Law School >>> Twitter/XStanford Lawyer Magazine >>> Twitter/X(00:00) Research Funding (05:01) The Competitive Grant Process (15:01) Addressing Disease Burden (20:00) Impacts of Stopped Clinical Trials (25:01) The Role of Federal Investment in Innovation 

It's an Arg1 extravaganza as Reena Sharma, Sara Olofsson, Karolina Stepien and Alison Woodall discuss three separate papers looking at the Salford Royal experience of a cohort of adults with Arginase 1 deficiency and the wider health and societal burden of the condition. Retrospective analysis of arginase 1 deficiency progression in adults over 5 years at a single metabolic centre Reena Sharma et al https://doi.org/10.1002/jmd2.12450 Disease burden among patients with Arginase 1 deficiency and their caregivers: A multinational, cross-sectional survey Sara Olofsson et al https://doi.org/10.1002/jmd2.12456 Societal costs and quality of life associated with arginase 1 deficiency in a European setting – a multinational, cross-sectional survey Sara Olofsson et al https://doi.org/10.1080/13696998.2024.2400856

Commentary by Dr. Jian'an Wang.

Commentary by Dr.  Ethan Katznelson.

In this podcast, expert clinicians will discuss the current tools for quantifying disease severity and burden in patients with gMG.  To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/neurology/20250220/1-understanding-disease-burden-and-severity-in-gmg

Have you ever wondered what it takes for a startup, particularly in a niche field like women's health, to secure the necessary funding to move forward and make a meaningful impact? In this episode of The Angel Next Door Podcast, Marcia Dawood sits down with Mark Gannott, who brings a unique blend of neuroscience, economics, and entrepreneurship to the table. From navigating the complex landscape of women's health financing to shedding light on economic modeling and network strategies, Mark's insights are invaluable for anyone looking to understand the intricacies of funding in highly specialized areas.Mark Gannott, an economist and pharmacoeconomist, has a scholarly background in neuroscience and economics. His career took a pivotal turn following a personal tragedy that shifted his focus from medical school to the financing side of healthcare. With a side project in managing a massively popular social media page focused on dogs and mental health, Mark works on critical health issues, including cannabis economics and underfunded areas like endometriosis. His drive to bring more financial resources to women's health startups sets him apart as a thought leader in this space.In this enlightening conversation, Mark explores why women's health is still struggling to garner sufficient funding despite its massive economic potential. He talks about his work as a pharmacoeconomist and the significance of building financial models that make compelling cases for investment in women's health. Additionally, the episode highlights the importance of network analysis in connecting the right people to foster successful startups. Whether you're an investor, an entrepreneur, or someone passionate about women's health, this episode provides crucial insights into an often-overlooked yet vital sector. Mark's forward-thinking approach to financing and network building makes this episode a must-listen for anyone interested in transforming the landscape for women's health. To get the latest from Mark Gannott, you can follow him below!LinkedIn - https://www.linkedin.com/in/markgannott/ Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma. To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CRE865. CME/MOC/AAPA credit will be available until June 19, 2025.Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Insmed.Disclosure information is available at the beginning of the video presentation.

This podcast brought to you Healthy Male is in association with Men's Health Week, June 10 - June 16 2024. A/Prof Tim Moss discusses what is impacting the health and wellbeing of Australian men and how we can support males to adopt healthy behaviours. Visit https://medcast.com.au/education/healthy-male for episode notes and more free education resources.

Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304791 - 1.0 - 05/2024 MAT-US-2404998 v1.0  - P Expiration Date: 05/15/2026

In 2021 on Episode 13, Vor Bio's President and CEO, Dr. Robert Ang shared data about the company's lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants. They also talk through Vor's decision to build an internal cell therapy manufacturing facility co-located with their Cambridge, MA-based headquarters.

No seu trigésimo oitavo episódio, o Estudos Medievais recebe Gabriel Cordeiro, doutorando pela Universidade de São Paulo, para uma conversa sobre a primeira pandemia de peste, também conhecida como Peste Justiniana. O pesquisador aborda questões biológicas da peste, incluindo sua forma de propagação, o agente patogênico e os sintomas associados à doença. Além disso, explora os primeiros relatos da manifestação da doença. Por fim, discute as interpretações mais recentes dos historiadores sobre o impacto dessa pandemia na região do Mediterrâneo. Participantes Carolina Santos Gabriel Cordeiro Membros da equipe ⁠⁠⁠⁠⁠⁠Carolina⁠ Santos (edição)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Cecília Silva (edição)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Diego Pereira (roteiro)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Eric Cyon (edição)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Gabriel Cordeiro (ilustração)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Isabela Silva (roteiro)⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠José Fonseca (roteiro)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Marina Sanchez (roteiro)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rafael Bosch (roteiro)⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sara Oderdenge (roteiro) Recomendações bibliográficas GREEN, Monica H. Climate and Disease in Medieval Eurasia. In: LUDDEN, David. Oxford Research Encyclopedia of Asian History. Nova Iorque: Oxford University Press, 2018. MORDECHAI, Lee; EISENBERG, Merle; NEWFIELD, Timothy; IZDEBSKI, Adam, KAY, Janet; POINAR, Hendrik. The Justinianic Plague: An Inconsequential Pandemic? Proceedings of the National Academy of Sciences, v. 116, n. 51, p. 25546-25554, 2019 NEWFIELD, Timothy. Mysterious and Mortiferous Clouds: The Climate Cooling and Disease Burden of Late Antiquity. in: IZDEBSKI, Adam; MULRYAN, Michael (Eds.). Environment and Society in the Long Late Antiquity. Leiden: Brill, p. 89-115, 2018. SARRIS, Peter. New Approches to the ‘Plague of Justinian'. Past & Present, v. 254, n. 1, p. 315-346, 2022. WIECHMANN, Ingrid; GRUPE, Gisela. Detection of Yersinia pestis DNA in two early medieval skeletal finds from Aschheim (Upper Bavaria, 6th century A.D.). American Journal of Physical Anthropology, v. 126, n. 1, p. 48–55, 2004.

As Women's History Month comes to its final week, today's podcast sees web editor Nicole Raleigh in conversation with Debra Weiss, COO of the Bill & Melinda Gates Medical Research Institute (Gates MRI), discussing her role as a female leader in the leader and the non-profit organisation's work in developing novel biomedical interventions and lessening the burden of disease in LMICs.

In this opening conversation on MASLD disease burden, Zobair Younossi summarizes and expands on some key points from the recent Diabetes Spectrum review article he co-authored with Linda Henry.Zobair starts by discussing the recent review article, Understanding the Burden of Non-Alcoholic Fatty Liver Disease: Time for Action which he describes as "a summary of a large body of evidence that's being generated." He points to three pivotal issues:The treatment burden associated with MASLD and MASH is extremely high and will grow over time. The prevalence of MASLD in the overall population has grown to ~38%, but for Type 2 diabetics, who have worse outcomes associated with MASLD, this number is 68%. MASH numbers are estimated to be 5-7% in the general population, but 37% among T2D patients. As diabetes increases across the globe, these rates will go higher.The humanistic burden, as measured in Quality of Life scores, is also significant. Patients living with MASLD and MASH report lower QoL scores, which translates not only into a less happy, more depressed society, but also into significant indirect economic effects due to poorer worker performance and, presumably, more time away from work. The economic burden of MASLD is significant in every country, but the scale and structure of this burden varies from country to country. Key drivers include dietary issues and inactivity, and issues are becoming more pronounced globally. These economic issues are driven largely by the key downstream sequelae. The leading causes of death from MASLD are cardiovascular disease and extrahepatic cancers, which are costly, and patients with cirrhosis are highly susceptible to liver cancer as well. Jörn Schattenberg joins the conversation to commend Zobair on his work, which, as Jörn puts it,  "educate[s] us as physicians on where the risk factors and the at-risk populations are, and we're moving that way. I mean, we're trying to focus on patients with diabetes that are more advanced from the hepatologist perspective." He also discusses the ongoing effort to educate endocrinologists and primary care about these issues as well, since those two specialties treat the lion's share of diabetic patients. Zobair goes on to describe the Markov models of disease cost his group has built already in seven countries, and plans to build in more. Key point: MASLD is costly everywhere, but the structure of cost and, most importantly, public health solutions will vary from country to country.

Initially, this conversation focuses on how cost-effectiveness issues relate to the MASLD Disease Burden. In the process, Zobair Younossi provides education on some of the metrics and concepts pivotal to drug value assessment.Roger Green starts off asking how the economics of treating MASH stack up against hypercholesterolemia at the birth of statins in the 1980s, where the medical benefit was clear but economic was harder to manage. Zobair proceeds to describe the process by which the cost effectiveness of drugs is measured, computation of Quality Adjusted Life Years, or QALYs, and how different countries vary in the level of QALYs they consider cost effective. He also notes that within the US, at least, we may be willing to accept five times greater cost per QALY than for another. He also points out that cost effectiveness grows as new therapeutic options include price competition into a market.Louise Campbell shares the specific US cost numbers from Zobair's article, which she describes as “frightening,” particularly given the rate of growth in the disease and society's lack of efficacy in shifting the curve on this. Zobair responds by saying that one goal of the article was to create awareness that regular surveillance of diabetic patients for MASLD could have a significant economic impact in the US. As the conversation winds down, Jörn Schattenberg comments that all this is a team effort and Zobair agrees heartily.

Season four of Getting to Know You shakes up our format with a new twist. This season, we are getting to know the amazing research that PeDRA members are doing. In our first episode, nurse practitioner, Emily Croce, PhD, MSN, APRN, CPNP-PC talks us through her 2022 Childhood Eczema Challenge grant, The Role of Outdoor Air Pollution on Disease Burden and Racial Ethnic Disparities. Learn how this project made use of existing data to reveal some key findings, the tools and methodology used in this study, and how this project is going to fuel future research into the intersection of atopic diseases and racial and ethnic disparities. You can view Emily's collaborative publication here.

This one is for the kids. Long COVID can affect anyone at any age, but growing up with a chronic illness means you are learning who you are while realising who you will never be. This one is for the epidemic survivors who are still here, still around, even though the disease that changed your life is no longer the hot topic. This one is for the people living with post-polio who were told it was all in their heads. If that sounds familiar, this one is for you too. It's for all of us. We need to talk to each other. CN: This episode contains discussions of medical disbelief and trauma. Texts mentioned in this episode: (Referenced by Katie Bourdeau): COVID Long-Haulers Canada, Statement from the Chief Public Health Officer of Canada on July 7, 2021, Prevalence of long-term effects in individuals diagnosed with COVID-19: a living systematic review Van Lier et al: Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011 Ruth Bridgen's thesis: Postpolio syndrome—“We aren't dead yet” The Office of National Statistics March 2023 report I would like to thank the British Polio Fellowship for connecting me with Frances and Ruth. Full transcripts and references are available at www.massivelydisabled.com Please rate and review Massively Disabled on Apple Podcasts and Spotify. This helps other people find the show. You can follow the show on Instagram and Twitter @massdisabledpod Hosting, producing, and editing is done by Élaina Gauthier-Mamaril Music is by Morgan Kluck-Keil This podcast is made with the support of the Centre for Biomedicine, Self and Society, Usher Institute, at the University of Edinburgh.

Did you know that adding basal insulin to patients who remain above target despite an optimal guideline-recommended antidiabetes regimen can further reduce HbA1c levels by up to 3 percentage points? Credit available for this activity expires: 11/14/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998367?ecd=bdc_podcast_libsyn_mscpedu

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

In this episode, hosts Drs. Jennifer Lee and Jason Silverman debrief with  Dr. Sandeep Gupta on his NASPGHAN Research Year in Review.  Dr. Gupta is Professor of Pediatrics at the University of Alabama He is also the North American Editor and Chief for both JPGN and JPGN Reports.  Learning Objectives:Review impactful clinical research papers in eosinophilic gastrointestinal disorders, celiac disease, and inflammatory bowel disease from 2023Review impactful clinical research papers in hepatology from 2023 Review impactful clinical research papers in nutrition and obesity medicine from 2023Executive Summary: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity - PubMed (nih.gov)Once-Weekly Semaglutide in Adolescents with Obesity - PMC (nih.gov) Analysis of INSPPIRE-2 Cohort: Risk Factors and Disease Burden in Children With Acute Recurrent or Chronic Pancreatitis - PubMed (nih.gov)Pancreatitis-Associated Medication Use in Hospitalized Pediatric and Young Adult Patients With Acute Pancreatitis - PubMed (nih.gov)International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature - PubMed (nih.gov)A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions - PubMed (nih.gov)Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick - PubMed (nih.gov)A multisociety Delphi consensus statement on new fatty liver disease nomenclature - PubMed (nih.gov)Gut enterochromaffin cells drive visceral pain and anxiety | NatureSupport the showMerch website As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes! Support the show As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes!

“We've come in with an offering that's broader and deeper than a lot of data aggregators, but on top of that we've built really simple software that allows people in a no-code sort of way to just ask questions that they can get answers to instantly, and that's why we're winning,” Komodo Health cofounder and CEO Arif Nathoo explains. In this episode of the Vanguards of Health Care podcast, Nathoo sits down with Bloomberg Intelligence analyst Jonathan Palmer for a detailed discussion on the origins of Komodo's data and analytics platform, the nuances that differentiate it for enterprise customers and the power of its longitudinal Healthcare Map database.See omnystudio.com/listener for privacy information.

In a study recently published in “ACR Open Rheumatology” titled: “Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States“, first author Dr. Sharon Dowell set out to understand some of the factors associated with regional variation of rheumatoid arthritis in the United States. Sharon Dowell, MD presents her study's findings and conclusions. ACR's RISE Team member, Tracy Johansson, MS, joins us as well to discuss how RISE attempts to close these gaps. Together, both of our guests help us to understand how geographic location contributes to a disproportionate level of care for those with RA and what we can do about it. 

New analysis from the Australian Institute of Health and Welfare explored what could happen if Australians reduced their body mass index or were more physically active between 2018 and 2030. It found that small improvements could have a big effect on the disease burden attributable to being overweight and inactive. But medical experts warn the government is not doing enough to encourage Australians to make healthy choices. - Het Australian Institute of Health and Welfare heeft onderzocht wat er zou kunnen gebeuren als Australiërs hun BMI ofwel hun body mass index zouden verlagen of fysiek meer actief zouden worden tussen 2018 en 2030. Uit de analyse blijkt dat kleine verbeteringen een groot effect kunnen hebben op de ziektelast door overgewicht en inactiviteit. Medische experts waarschuwen dat de regering Australiërs niet genoeg aanmoedigt gezonde keuzes te maken.

Angela R. Branche, MD, FIDSA, and Laura P. Hurley, MD, MPH, discuss research on PCPs' perceptions of RSV disease burden; current RSV testing practices; and potential barriers to adoption of any RSV vaccine.

In this podcast, an experienced conference and webinar moderator is joined by two doctors in the field of paediatric infectious diseases: David Greenberg and Maria Hemming-Harlo. In this podcast, our guest experts provide information and their perspectives on the following topics: The disease burden of rotavirus The related morbidity and mortality of rotavirus How rotavirus is transmitted The clinical picture of rotavirus infection The evidence supporting routine vaccination with RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent) This podcast was funded by Merck Sharp & Dohme LLC. Below please find the reference list for Vax Voices, Podcast 1: The Global Burden of Rotavirus Disease and Evidence Supporting Routine Vaccination With RotaTeq to ensure listeners can further explore the content discussed. View the product information and indication for RotaTeq here. View the Select Safety Information from MSD below. Select Safety Information RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine. Infants with a history of intussusception or who have congenital malformation of the gastrointestinal tract that could predispose infants to intussusception should not receive RotaTeq. Infants with Severe Combined Immunodeficiency Disease or SCID should not receive RotaTeq. Administration of RotaTeq should be postponed in infants suffering from acute severe febrile illness. The presence of a minor infection is not a contraindication for immunisation. The administration of RotaTeq should be postponed in subjects suffering from acute diarrhoea or vomiting. No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised. Cases of gastroenteritis associated with vaccine virus have been reported post marketing in infants with severe combined immunodeficiency. Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts. In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq. As a precaution, healthcare professionals should follow-up on any symptoms indicative of intussusception (severe abdominal pain, persistent vomiting, bloody stools, abdominal bloating and/or high fever) since data from observational studies indicate an increased risk of intussusception, mostly within 7 days after rotavirus vaccination. Parents/guardians should be advised to promptly report such symptoms to their healthcare provider. The level of protection provided by RotaTeq is based on the completion of all 3 doses. As with any vaccine, vaccination with RotaTeq may not result in complete protection in all recipients. HQ-ROT-00133 | 02/23   Podcast References: 1.Nelson R. COVID-19 disrupts vaccine delivery. Lancet Infect Dis. 2020;20(5):546. 2.Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Chapter 19: Rotavirus. Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/rota.html. Last accessed: 6 March 2023. 3.Dormitzer PR. "Rotaviruses," Mandell GL, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier Saunders; 2019:1983-96. 4.Centers for Disease Control and Prevention (CDC). Rotavirus. Clinical information. 2021. Available at: https://www.cdc.gov/rotavirus/clinical.html. Last accessed: 13 October 2022. 5.Troeger C et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172(10):958-965. Erratum in: JAMA Pediatr. 2022;176(2):208. 6.GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(9):909-948. Erratum in: Lancet Infect Dis. 2017 Sep;17(9):897. 7.Van Damme P et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis. 2006;6(12):805-12. 8.Paul MO, Erinle EA. Influence of humidity on rotavirus prevalence among Nigerian infants and young children with gastroenteritis. J Clin Microbiol. 1982;15(2):212-5. 9.Finnish Institute for Health and Welfare. Infectious diseases and vaccines: rotavirus vaccine. 2020. Available at: https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/rotavirus-vaccine. Last accessed: 16 September 2022. 10.GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. 11.Franco MA et al. Immunity and correlates of protection for rotavirus vaccines. Vaccine. 2006;24(15):2718-31. 12.Gentsch JR et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005;192(Suppl 1):S146-59. 13.Merck & Co. RotaTeq®. Prescribing information. 2022. Available at: https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf. Last accessed: 4 January 2023. 14.European Medicine Agency (EMA). RotaTeq. Summary of product characteristics. 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf. Last accessed: 4 January 2023. 15.Velasquez-Portocarrero DE et al. Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial. Lancet Infect Dis. 2022;22(11):1606-16. 16.Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009;58(RR-2):1-25. 17.Vesikari T et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33. 18.Vesikari T et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007;11(Suppl 2):S29-35. 19.Heyse JF; REST Study Team. Evaluating the safety of a rotavirus vaccine: the REST of the story. Clin Trials. 2008;5(2):131-9. 20.World Health Organization (WHO). Rotavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2021;96(28):301-20.  

Angela R. Branche, MD, FIDSA, and Laura P. Hurley, MD, MPH, continue their discussion of the history, epidemiology, clinical burden, morbidity, and mortality of RSV in adults, particularly in vulnerable subgroups such as older adults or adults with cardiopulmonary conditions.

On this episode, Dr. Kevin Kuo and Laurice Levine are recording in New Orleans where they take an existential dive into the concept of “disease burden” in Thalassemia. SHOW DESCRIPTION Thal Pals: The Alpha Beta Revolution Podcast is intended for patients, caregivers, providers, and the greater community of people who are impacted by Thalassemia.  Each episode, Thal Pals strives to provide listeners with critical education, the latest scientific updates, and voices from the Thalassemia community.   TRANSPARENCY STATEMENT  Thal Pals: The Alpha Beta Revolution Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Hosts and guest featured in this episode have been compensated for their time.  

Laura P. Hurley, MD, MPH, and Angela R. Branche, MD, FIDSA, discuss the history, epidemiology, clinical burden, morbidity, and mortality of RSV in adults, particularly in vulnerable subgroups such as older adults or adults with cardiopulmonary conditions.

Rose Eveleth is a futurologist – a title they prefer over the serious nature of the label “futurist.” They're the creator of a podcast network that demystifies the future, were recently featured on Netflix's The Future of Everything & a writer who explores how humans tangle with science & tech. In this episode, we explore (with much hilarity) the ethics & impacts of future technology including smart cities, artificial intelligence & data privacy.If you liked this episode, you'll also like episode 118: GMO MOSQUITOES?! ETHICS, DISEASE BURDEN & THE FUTUREGuest: https://www.instagram.com/roseveleth/ | https://www.linkedin.com/in/rose-eveleth-61759116/ | https://twitter.com/roseveleth | https://roseveleth.com/Host:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovertSponsors: https://uwf.edu/university-advancement/departments/historic-trust/ | https://www.ensec.net/

CME credits: 1.25 Valid until: 21-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/amkd-disease-burden-and-management-strategies-the-need-for-small-molecule-treatments/14538/ This program discusses the need to increase awareness about APOL1-Mediated Kidney Disease (AMKD), the clinical impact of genotyping for early diagnosis, disease management, and the need for new small-molecule drug treatments. There is currently a lack of awareness among key decision-makers and in the Black community regarding the health disparities and the importance of genotyping in AMKD. Increasing awareness among nephrologists, hospitalists, geneticists, and patient communities on the impact of early genotyping for APOL1 in Black patients have the potential to improve outcomes and reduce health disparities. Moreover, increasing awareness among nephrologists and patient networks may improve clinical trial participation among underrepresented communities, which can directly impact the development of new AMKD treatments.

Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. Diffuse alveolar hemorrhage in antiphospholipid syndrome Dr. Eric Dein discusses Abstract 0675 at ACR22 Convergence. Abstract 0675: Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at ACR22 Convergence. Abstract 0872: Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis Gender differences in Axial Spondyloarthritis Dr. Antoni Chan covered abstracts 0497 and 1614 at ACR22 Convergence in Philadelphia, PA. Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE Dr. Sheila Reyes discusses abstract 1654 at ACR22 Convergence.  Abstract 1654: Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence.  Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence.  Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Meredith Danberg-Ficarelli is a  zero waste consultant and executive director of Common Ground Compost, a New York organization dedicated to waste reduction through zero waste program design, staff training, education, advocacy, collection & compost. Here she explains how trash & recycling really work, the socioeconomic dynamics in environmental causes & how we can be less trashy.If you liked this episode, you'll also like episode 118: GMO MOSQUITOES?! ETHICS, DISEASE BURDEN & THE FUTUREGuest: https://www.linkedin.com/in/meredithdf/ | https://www.instagram.com/_garbagequeen_/ | https://www.instagram.com/commoncompost/ | https://www.facebook.com/commongroundcompost | https://commongroundcompost.com/ Host:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovertSponsors: Watch me on TV https://bit.ly/3ImiTat |   https://uwf.edu/university-advancement/departments/historic-trust/ | https://www.ensec.net/

The pandemic has been a global issue, which has benefitted from the coming together of industry, pharma, academia, non-governmental and governmental support. What the pandemic has also brought into sharp focus is the global imbalance access to healthcare and health inequity between the Global North and Global South. For this important conversation, we are joined by Professor Linda-Gail Bekker, Chief Operating Officer of the Desmond Tutu HIV Foundation about the current situation with HIV and TB in Africa, and the impact COVID-19 has had on patients already suffering from communicable diseases. So, what can we do? Lenias Hwenda, founder and CEO of Medicines for Africa, explains the additional problems of access to medicines and potential solutions for global vaccine inequity, working to make medicines as inexpensive as possible, and improving the supply chain. Related reading – Dzau, V.J., Balatbat, C.A., Offodile II, A.C., Closing the global vaccine equity gap: equitably distributed manufacturing. The Lancet. 2022;399(10339): 1924-1926. DOI: https://doi.org/10.1016/S0140-6736(22)00793-0 The Global Biopharma Resilience Index How localizing manufacturing is helping the Middle East take control of its vaccine supply? Keywords: equitable access, HIV, human immunodeficiency viruses, Lentivirus, medicines, pandemic, countries, vaccine, TB, epidemic, Africa, supply chain, communicable diseases, middle-income countries, access, low-income countries, Global North, Global South, disease burden.

In April of 2021, GMO mosquitos were released in the Florida Keys, but as Molecular Biologist, Dr. Natalie Kofler explains, they have been released in other regions prior to that. She helps shed light on the difference between GMO mosquitos and gene drive mosquitoes & the global impact of diseases spread by mosquitoes. We also take a deep dive into the ethical questions around who is creating these lab-altered insects & who is impacted by their release into the wild.Guest: https://www.editingnature.org/  |  https://twitter.com/nataliekofler  |  https://twitter.com/EditingNatureHost:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovertSponsors: https://uwf.edu/university-advancement/departments/historic-trust/ | https://www.ensec.net/

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient's ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Food is our happy place, literally! Did you know that 95% of serotonin is produced in our gastrointestinal tract (G.I.)? The link between proper nutrition and good health is well-documented, yet most healthcare providers are taught very little about the natural healing power of food. Worse are the barriers between insurance providers and dieticians like our guest, Denine Rogers MS, RDN, L.D., FAND. Instead of using a proper balanced diet, exercise and nutrition to heal, we are often taught to treat patients with pharmaceuticals. Today, we speak to Denine Rogers, registered dietitian and licensed nutritionist, about the need for more black dieticians, barriers within the field, and how physicians and dieticians can work together to create a complete and individualized wellness plan. Key Takeaways: [00:01:53] Meet Denine Rogers MS, RDN, LD, FAND [00:03:49] What inspired her to become a dietitian [00:13:54] Why the culture needs more black dieticians and how to get started [00:14:04] Challenges that dieticians face and how to overcome them [00:17:44] How Denine is leading the charge to recruit more dieticians [00:23:50] Reframing weight loss to make better food choices Takeaways to help you Cure The Culture: Denine did not aspire to be a dietitian and nutritionist. It was an internship and the encouragement of Paula Sneed, the first black Senior Vice President of Global Marketing Resources & Initiatives at Kraft Foods, Inc., that exposed her to the industry. Her experience highlights the importance of mentorship in the black community. Healthy living is marketed as aspirational instead of a fundamental human right. This causes underrepresented communities to shy away from healthy lifestyle changes. In this interview, Denine explains the mental and physical roadblocks that prevent patients from experiencing the healing benefits of food and how dieticians and physicians can begin to work together.

Vascular surgeon Oliver Aalami, M.D. discusses his research in clinical validation devices, algorithms from step-count data, and health data accessibility for patients. This episode is part of a Health IT series by the AMA-MSS Committee on Health Information Technology, hosted by Kristofer Jackson, medical student at the University of Toledo College of Medicine.